TAKEDA PHARMACEUTIC-SP ADR (TAK) Stock Fundamental Analysis
USA - New York Stock Exchange - NYSE:TAK - US8740602052 - ADR
15.65 USD
+0.07 (+0.45%)
15.65 USD
0 (0%)
We assign a fundamental rating of 5 out of 10 to TAK. TAK was compared to 192 industry peers in the Pharmaceuticals industry. While TAK has a great profitability rating, there are quite some concerns on its financial health. TAK has a correct valuation and a medium growth rate. TAK also has an excellent dividend rating.
1. Profitability
1.1 Basic Checks
In the past year TAK was profitable.
In the past year TAK had a positive cash flow from operations.
TAK had positive earnings in each of the past 5 years.
TAK had a positive operating cash flow in each of the past 5 years.
1.2 Ratios
TAK has a better Return On Assets (0.23%) than 78.13% of its industry peers.
Looking at the Return On Equity, with a value of 0.46%, TAK is in the better half of the industry, outperforming 79.69% of the companies in the same industry.
Looking at the Return On Invested Capital, with a value of 1.87%, TAK is in the better half of the industry, outperforming 79.17% of the companies in the same industry.
The Average Return On Invested Capital over the past 3 years for TAK is significantly below the industry average of 12.85%.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 0.23% | ||
| ROE | 0.46% | ||
| ROIC | 1.87% |
ROA(3y)1.33%
ROA(5y)1.73%
ROE(3y)2.84%
ROE(5y)3.97%
ROIC(3y)2.62%
ROIC(5y)2.55%
1.3 Margins
TAK has a better Profit Margin (0.75%) than 78.13% of its industry peers.
In the last couple of years the Profit Margin of TAK has grown nicely.
TAK has a Operating Margin of 8.46%. This is amongst the best in the industry. TAK outperforms 80.21% of its industry peers.
TAK's Operating Margin has improved in the last couple of years.
Looking at the Gross Margin, with a value of 64.60%, TAK is in the better half of the industry, outperforming 73.44% of the companies in the same industry.
In the last couple of years the Gross Margin of TAK has remained more or less at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 8.46% | ||
| PM (TTM) | 0.75% | ||
| GM | 64.6% |
OM growth 3Y-8.47%
OM growth 5Y6.13%
PM growth 3Y-28.5%
PM growth 5Y11.87%
GM growth 3Y-1.71%
GM growth 5Y-0.42%
2. Health
2.1 Basic Checks
TAK has a Return on Invested Capital (ROIC), which is just above the Cost of Capital (WACC), which means it is creating some value.
Compared to 1 year ago, TAK has more shares outstanding
The number of shares outstanding for TAK has been increased compared to 5 years ago.
The debt/assets ratio for TAK has been reduced compared to a year ago.
2.2 Solvency
TAK has an Altman-Z score of 1.19. This is a bad value and indicates that TAK is not financially healthy and even has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of 1.19, TAK is in line with its industry, outperforming 52.60% of the companies in the same industry.
TAK has a debt to FCF ratio of 5.04. This is a neutral value as TAK would need 5.04 years to pay back of all of its debts.
TAK has a Debt to FCF ratio of 5.04. This is amongst the best in the industry. TAK outperforms 82.81% of its industry peers.
TAK has a Debt/Equity ratio of 0.61. This is a neutral value indicating TAK is somewhat dependend on debt financing.
TAK has a worse Debt to Equity ratio (0.61) than 68.23% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.61 | ||
| Debt/FCF | 5.04 | ||
| Altman-Z | 1.19 |
ROIC/WACC1.16
WACC1.61%
2.3 Liquidity
A Current Ratio of 1.36 indicates that TAK should not have too much problems paying its short term obligations.
The Current ratio of TAK (1.36) is worse than 73.44% of its industry peers.
TAK has a Quick Ratio of 1.36. This is a bad value and indicates that TAK is not financially healthy enough and could expect problems in meeting its short term obligations.
Looking at the Quick ratio, with a value of 0.76, TAK is doing worse than 84.38% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.36 | ||
| Quick Ratio | 0.76 |
3. Growth
3.1 Past
The earnings per share for TAK have decreased strongly by -88.38% in the last year.
TAK shows quite a strong growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 19.20% yearly.
Looking at the last year, TAK shows a decrease in Revenue. The Revenue has decreased by -2.84% in the last year.
The Revenue has been growing slightly by 6.84% on average over the past years.
EPS 1Y (TTM)-88.38%
EPS 3Y-22.57%
EPS 5Y19.2%
EPS Q2Q%-112.87%
Revenue 1Y (TTM)-2.84%
Revenue growth 3Y8.68%
Revenue growth 5Y6.84%
Sales Q2Q%-5.38%
3.2 Future
Based on estimates for the next years, TAK will show a very strong growth in Earnings Per Share. The EPS will grow by 46.55% on average per year.
Based on estimates for the next years, TAK will show a small growth in Revenue. The Revenue will grow by 0.19% on average per year.
EPS Next Y96.76%
EPS Next 2Y70.53%
EPS Next 3Y46.55%
EPS Next 5YN/A
Revenue Next Year-1.53%
Revenue Next 2Y-0.48%
Revenue Next 3Y0.19%
Revenue Next 5YN/A
3.3 Evolution
The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
4. Valuation
4.1 Price/Earnings Ratio
Based on the Price/Earnings ratio of 223.57, the valuation of TAK can be described as expensive.
76.04% of the companies in the same industry are more expensive than TAK, based on the Price/Earnings ratio.
Compared to an average S&P500 Price/Earnings ratio of 26.57, TAK is valued quite expensively.
Based on the Price/Forward Earnings ratio of 24.59, the valuation of TAK can be described as rather expensive.
Compared to the rest of the industry, the Price/Forward Earnings ratio of TAK indicates a somewhat cheap valuation: TAK is cheaper than 75.00% of the companies listed in the same industry.
TAK's Price/Forward Earnings ratio indicates a similar valuation than the S&P500 average which is at 24.04.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 223.57 | ||
| Fwd PE | 24.59 |
4.2 Price Multiples
TAK's Enterprise Value to EBITDA ratio is rather cheap when compared to the industry. TAK is cheaper than 87.50% of the companies in the same industry.
TAK's Price/Free Cash Flow ratio is rather cheap when compared to the industry. TAK is cheaper than 93.75% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 8.36 | ||
| EV/EBITDA | 10.32 |
4.3 Compensation for Growth
The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates TAK does not grow enough to justify the current Price/Earnings ratio.
The decent profitability rating of TAK may justify a higher PE ratio.
A more expensive valuation may be justified as TAK's earnings are expected to grow with 46.55% in the coming years.
PEG (NY)2.31
PEG (5Y)11.65
EPS Next 2Y70.53%
EPS Next 3Y46.55%
5. Dividend
5.1 Amount
With a Yearly Dividend Yield of 4.46%, TAK is a good candidate for dividend investing.
TAK's Dividend Yield is rather good when compared to the industry average which is at 0.45. TAK pays more dividend than 96.35% of the companies in the same industry.
TAK's Dividend Yield is rather good when compared to the S&P500 average which is at 1.88.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 4.46% |
5.2 History
The dividend of TAK has a limited annual growth rate of 1.18%.
TAK has paid a dividend for at least 10 years, which is a reliable track record.
TAK has not decreased its dividend in the last 3 years.
Dividend Growth(5Y)1.18%
Div Incr Years2
Div Non Decr Years3
5.3 Sustainability
935.06% of the earnings are spent on dividend by TAK. This is not a sustainable payout ratio.
TAK's earnings are growing more than its dividend. This makes the dividend growth sustainable.
DP935.06%
EPS Next 2Y70.53%
EPS Next 3Y46.55%
15.65
+0.07 (+0.45%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners46.91%
Inst Owner Change8.68%
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap49.44B
Revenue(TTM)4.42T
Net Income(TTM)33.08B
Analysts73.68
Price TargetN/A
Short Float %0.36%
Short Ratio4.02
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 4.46% |
Yearly Dividend0.61
Dividend Growth(5Y)1.18%
DP935.06%
Div Incr Years2
Div Non Decr Years3
Ex-Date
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-41.49%
Min EPS beat(2)-121.92%
Max EPS beat(2)38.94%
EPS beat(4)1
Avg EPS beat(4)-35.42%
Min EPS beat(4)-121.92%
Max EPS beat(4)38.94%
EPS beat(8)4
Avg EPS beat(8)-31.47%
EPS beat(12)6
Avg EPS beat(12)-33.69%
EPS beat(16)7
Avg EPS beat(16)-40.61%
Revenue beat(2)0
Avg Revenue beat(2)-6.4%
Min Revenue beat(2)-6.76%
Max Revenue beat(2)-6.04%
Revenue beat(4)0
Avg Revenue beat(4)-3.84%
Min Revenue beat(4)-6.76%
Max Revenue beat(4)-0.48%
Revenue beat(8)4
Avg Revenue beat(8)3.03%
Revenue beat(12)7
Avg Revenue beat(12)3.44%
Revenue beat(16)11
Avg Revenue beat(16)3.69%
PT rev (1m)-2.56%
PT rev (3m)-7.92%
EPS NQ rev (1m)15.75%
EPS NQ rev (3m)28.76%
EPS NY rev (1m)-7.36%
EPS NY rev (3m)-11.74%
Revenue NQ rev (1m)1.73%
Revenue NQ rev (3m)1.7%
Revenue NY rev (1m)-0.31%
Revenue NY rev (3m)-0.48%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 223.57 | ||
| Fwd PE | 24.59 | ||
| P/S | 1.75 | ||
| P/FCF | 8.36 | ||
| P/OCF | 6.43 | ||
| P/B | 1.08 | ||
| P/tB | N/A | ||
| EV/EBITDA | 10.32 |
EPS(TTM)0.07
EY0.45%
EPS(NY)0.64
Fwd EY4.07%
FCF(TTM)1.87
FCFY11.96%
OCF(TTM)2.43
OCFY15.56%
SpS8.96
BVpS14.47
TBVpS-3.25
PEG (NY)2.31
PEG (5Y)11.65
Graham Number4.77
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 0.23% | ||
| ROE | 0.46% | ||
| ROCE | 3.03% | ||
| ROIC | 1.87% | ||
| ROICexc | 1.99% | ||
| ROICexgc | 8.07% | ||
| OM | 8.46% | ||
| PM (TTM) | 0.75% | ||
| GM | 64.6% | ||
| FCFM | 20.88% |
ROA(3y)1.33%
ROA(5y)1.73%
ROE(3y)2.84%
ROE(5y)3.97%
ROIC(3y)2.62%
ROIC(5y)2.55%
ROICexc(3y)2.76%
ROICexc(5y)2.73%
ROICexgc(3y)14.61%
ROICexgc(5y)14.15%
ROCE(3y)4.25%
ROCE(5y)4.14%
ROICexgc growth 3Y-6.2%
ROICexgc growth 5Y8.09%
ROICexc growth 3Y-3.88%
ROICexc growth 5Y10.72%
OM growth 3Y-8.47%
OM growth 5Y6.13%
PM growth 3Y-28.5%
PM growth 5Y11.87%
GM growth 3Y-1.71%
GM growth 5Y-0.42%
F-Score6
Asset Turnover0.31
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.61 | ||
| Debt/FCF | 5.04 | ||
| Debt/EBITDA | 3.9 | ||
| Cap/Depr | 37.3% | ||
| Cap/Sales | 6.28% | ||
| Interest Coverage | 3.04 | ||
| Cash Conversion | 107.4% | ||
| Profit Quality | 2788.5% | ||
| Current Ratio | 1.36 | ||
| Quick Ratio | 0.76 | ||
| Altman-Z | 1.19 |
F-Score6
WACC1.61%
ROIC/WACC1.16
Cap/Depr(3y)69.03%
Cap/Depr(5y)56.25%
Cap/Sales(3y)11.53%
Cap/Sales(5y)9.44%
Profit Quality(3y)309.71%
Profit Quality(5y)308.48%
High Growth Momentum
Growth
EPS 1Y (TTM)-88.38%
EPS 3Y-22.57%
EPS 5Y19.2%
EPS Q2Q%-112.87%
EPS Next Y96.76%
EPS Next 2Y70.53%
EPS Next 3Y46.55%
EPS Next 5YN/A
Revenue 1Y (TTM)-2.84%
Revenue growth 3Y8.68%
Revenue growth 5Y6.84%
Sales Q2Q%-5.38%
Revenue Next Year-1.53%
Revenue Next 2Y-0.48%
Revenue Next 3Y0.19%
Revenue Next 5YN/A
EBIT growth 1Y-31.07%
EBIT growth 3Y-0.52%
EBIT growth 5Y13.39%
EBIT Next Year435.35%
EBIT Next 3Y77.31%
EBIT Next 5YN/A
FCF growth 1Y613.62%
FCF growth 3Y-8.86%
FCF growth 5Y9.4%
OCF growth 1Y24.54%
OCF growth 3Y-2%
OCF growth 5Y9.54%
TAKEDA PHARMACEUTIC-SP ADR / TAK FAQ
What is the ChartMill fundamental rating of TAKEDA PHARMACEUTIC-SP ADR (TAK) stock?
ChartMill assigns a fundamental rating of 5 / 10 to TAK.
What is the valuation status of TAKEDA PHARMACEUTIC-SP ADR (TAK) stock?
ChartMill assigns a valuation rating of 5 / 10 to TAKEDA PHARMACEUTIC-SP ADR (TAK). This can be considered as Fairly Valued.
What is the profitability of TAK stock?
TAKEDA PHARMACEUTIC-SP ADR (TAK) has a profitability rating of 7 / 10.
Can you provide the expected EPS growth for TAK stock?
The Earnings per Share (EPS) of TAKEDA PHARMACEUTIC-SP ADR (TAK) is expected to grow by 96.76% in the next year.
How sustainable is the dividend of TAKEDA PHARMACEUTIC-SP ADR (TAK) stock?
The dividend rating of TAKEDA PHARMACEUTIC-SP ADR (TAK) is 7 / 10 and the dividend payout ratio is 935.06%.